Free Cash Flow

Aligos Therapeutics is using strategic stock grants to lure top talent. Is this a savvy growth play or a creeping cost for shareholders? We break it down.

After a painful restructuring, industrial manufacturer NN, Inc. is now exploring a sale. Is this the final step in its transformation or a capitulation?

With over 123 million displaced, refugee camps are now de facto cities. Temporary water solutions are fueling disease, making the case for permanent fixes.

The restaurant giant unveils a massive capital return plan, promising 100% of future free cash flow to investors while funding aggressive expansion in China.

Malaysia's Treasure Global secures fresh capital, but a brutal market reaction and high cash burn raise questions about its super app's future.

A $277M secondary offering sees MIAX shareholders cash in, but the company itself isn't taking any money. Here’s what that says about its financial power.

Lument Finance Trust's latest dividend boasts an attractive yield, but recent adjustments raise questions about the health of commercial real estate.

AMC's key governance reforms failed despite 90% voter support, stymied by low turnout. Meanwhile, a major share increase passed. What does this mean?

Zoetis boosts its dividend by 6%, but what does this move signal about the company's financial health and the booming global animal care market?

Tenaya Therapeutics seeks fresh capital to advance its heart disease pipeline, but the offering's structure raises dilution questions for investors.

A rejected $307M Danone offer and claims of poor governance fuel a bitter proxy fight at Lifeway Foods, pitting CEO against her largest shareholder—her brother.

From a Greenland mine to a Romanian refinery, a tech breakthrough is de-risking a vital new source of rare earths for the West's defense and green tech.

Cadrenal Therapeutics acquires a novel Phase 2 drug for a deadly clotting disorder, a strategic move targeting an underserved $1 billion market.

Roivant Sciences reveals accelerated timelines for key drugs and a bold three-year growth plan, pivoting its unique 'Vant' model toward commercialization.

Brink's new $750M share repurchase is more than a financial move; it’s a bold declaration that its digital transformation is generating serious cash.

Rezolute's stock plummets after its lead drug fails a key trial, raising questions about its future and highlighting the brutal realities of biotech.

Bill Ackman's fund posted a stellar 24.1% return. We dive into the high-conviction plays and innovative structure driving this market-beating performance.

A new contract for TGS in Brazil signals enduring appeal for offshore oil. Discover how 4D seismic is unlocking value in mature, complex energy fields.

South Korean tobacco giant KT&G just earned a flawless 'AAA' ESG rating, a first for its industry. What does this mean for investors and sustainability?

As CEO De Lyle Bloomquist announces his retirement, Rayonier Advanced Materials seeks a new leader to steer its ambitious 'BioFuture' strategy amid market volatility.